PPT-Glycemic Management of Type 2 Diabetes
Author : faustina-dinatale | Published Date : 2018-11-21
1 AACE Comprehensive Care Plan Handelsman YH et al Endocr Pract 201521suppl 1187 2 Therapeutic Lifestyle Change Glycemic Management of Type 2 Diabetes 3 Components
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Glycemic Management of Type 2 Diabetes" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Glycemic Management of Type 2 Diabetes: Transcript
1 AACE Comprehensive Care Plan Handelsman YH et al Endocr Pract 201521suppl 1187 2 Therapeutic Lifestyle Change Glycemic Management of Type 2 Diabetes 3 Components of Therapeutic Lifestyle Change. In-Hospital Management of Diabetes. Chapter 16. Robyn . Houlden. , . Sara . Capes, Maureen Clement, . David . Miller. CONTINUE. pre-hospital diabetes regimen if appropriate, otherwise …. USE. . insulin. 1c. Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes. Goals. HbA. 1c. Targets: HEDIS and ADA. Objectives for Treatment of T2D. ADA/EASD Recommendations for HbA. 1c. Approach for Individualizing Glycemic Targets. Glycemic. Variability for Diabetes Management. Matthew Wiley, . Razvan. . Bunescu. , Cindy Marling,. Jay . Shubrook. and Frank Schwartz. School of Electrical Engineering and Computer Science. Appalachian Rural Health Institute Diabetes and Endocrine Center. Efficacy and Safety of Antihyperglycemic Therapies Introduced Since 2004. 1. DPP-4 Inhibitors. 2. FDA-Approved Agents. Alogliptin. Linagliptin. Saxagliptin. Sitagliptin. Key Features. Oral administration. Efficacy and Safety of Modern Antihyperglycemic Therapies. 1. DPP-4 Inhibitors. 2. DPP-4 Inhibitors. FDA-Approved . Agents. Alogliptin. Linagliptin. Saxagliptin. Sitagliptin. Key . Features. Oral administration. Glimepiride, Metformin & . Voglibose. Combination in T2DM. Dr. Mohammed Riyaz . M.D (Medicine), Masters . in . Endocrinology(UK). Chief . Endocrinologist. & Medical Director (EDSC). Type 2 diabetes population requiring stringent . Help patients with type 2 diabetes achieve their glycemic goals. 1. In the US, diabetes is the primary diagnosis for . 37 million visits. to a physician’s office, emergency department or outpatient hospital-based clinic . Permission is required from the Association for any commercial use or for reproduction in any print materials. (contact . permissions@diabetes.org) . Standards of Medical Care in Diabetes - 2018. Standards of Care. Type 2 Diabetes. High blood glucose. Insulin secretion from pancreas. ↑ Glucose absorption by muscle. Low blood glucose. Eat. Analyzed genome sequence of Steve Quake. Rare protein altering SNPs . But usually do not know what the gene does, so difficult to know if the mutation is causing a trait.. National Center for Health in Public Housing Clinical Quality Working Group. Diabetes in PHPC Settings. HBA1c>9 in PHPC Settings. American Diabetes Association’s Press Release. The ADA has long recommended that treatment goals be individualized based on factors both modifiable and nonmodifiable, such as age, life expectancy, duration of disease, resources and support, and comorbid conditions. The ADA recommends that a reasonable A1C goal for many nonpregnant adults with type 2 diabetes is less than 7 percent based on the available evidence to date from the ACCORD, ADVANCE, VADT and UKPDS international clinical trials, which were evaluated and incorporated into ADA’s Standards of Care. . : Long-term hyperglycemia promotes development of complications and suboptimal well-being in patients with diabetes. A stringent glycemic control is a worldwide standard of diabetes care recommended i 1. . This number is only set to grow, with a prevalence of 14% in the US forecasted for 2060. 2. . A chronic metabolic disorder characterized by persistent hyperglycemia, the disease can lead to hypertension, coronary artery disease, peripheral diabetic neuropathy, and may progress to high risk of myocardial infarction or stroke. for HCSWs. Katharine Ramage. Diabetes MCN Professional Education Lead/DSN. Learning Outcomes. Develop an understanding of the different types of diabetes, risk factors for developing diabetes, how it can present and how it is diagnosed. ●. . Section . was . renamed. ●. . . N. ew recommendation. : . using . reliable data . metrics. ●. . . D. iscussion on . the social determinants of . health. ●. . . Te. lemedicine role.
Download Document
Here is the link to download the presentation.
"Glycemic Management of Type 2 Diabetes"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents